Cell Therapeutics, Inc. Patent applications |
Patent application number | Title | Published |
20130172338 | OXYGEN LINKED PYRIMIDINE DERIVATIVES - The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases. | 07-04-2013 |
20130018096 | PLATINUM COMPLEX WITH ANTITUMOR ACTIVITYAANM De Munari; SergioAACI MilanAACO ITAAGP De Munari; Sergio Milan ITAANM Di Giovine; StefanoAACI MilanAACO ITAAGP Di Giovine; Stefano Milan ITAANM Grugni; MarioAACI MilanAACO ITAAGP Grugni; Mario Milan ITAANM Nicoli; PaolaAACI MilanAACO ITAAGP Nicoli; Paola Milan ITAANM Paganelli; AlessandroAACI MilanAACO ITAAGP Paganelli; Alessandro Milan ITAANM Pardi; GianlucaAACI San Giuliano Terme (Pisa)AACO ITAAGP Pardi; Gianluca San Giuliano Terme (Pisa) ITAANM Pezzoni; GabriellaAACI MilanAACO ITAAGP Pezzoni; Gabriella Milan IT - The present invention relates to the antitumor compound of formula (I) a process for its preparation and pharmaceutical compositions containing it. | 01-17-2013 |
20120252717 | CONJUGATES OF BIOLOGICALLY ACTIVE PROTEINS HAVING A MODIFIED IN VIVO HALF-LIFE - Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide. | 10-04-2012 |
20110196123 | PROCESS FOR THE PREPARATION OF POLY-alpha-GLUTAMIC ACID AND DERIVATIVES THEREOF - The invention relates to an improved process for the preparation of poly-α-glutamic acids which comprises the polymerization of tertiary γ-esters of α-glutamic acid N-carboxy anhydride with appropriate solvents and initiators, followed by acid hydrolysis of the resulting poly-α-glutamic acid-γ-ester. The process is particularly advantageous in that it allows one to carefully control the molecular weight of the resulting poly-α-glutamic acid. The invention also relates to poly-α-glutamic acids capped at the amino terminus with carboxylic acids or amino acids and to a process for the preparation thereof. | 08-11-2011 |
20100189726 | LPAAT-BETA INHIBITORS AND USES THEREOF - The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity. | 07-29-2010 |
20100151582 | METHOD FOR DETERMINING THE AMOUNT OF CONJUGATED TAXANE IN POLYGLUT ACID-TAXANE CONJUGATES - The invention relates to a method for determining the amount of conjugated taxane, in particular paclitaxel, in a PGA-taxane conjugate said method comprising: a) reacting the PGA-taxane conjugate with a compound formula (I): R | 06-17-2010 |
20090298762 | CONJUGATES OF BIOLOGICALLY ACTIVE PROTEINS HAVING A MODIFIED IN VIVO HALF-LIFE - Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide. | 12-03-2009 |
20090130229 | Antitumor uses of compound - The use of an arylidene 2-indolinone derivative for treating tumors involving Met, PDGF-R, FGF-RI, FGF-R3 or Kit tyrosine kinases, or a Ret oncoprotein which includes a MEN2-associated mutation is disclosed. | 05-21-2009 |
20090099183 | PYRIMIDINES AND USES THEREOF - The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor-cells. | 04-16-2009 |
20080261980 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents - The invention relates to the use of compounds of general formula (I), in which R | 10-23-2008 |
20080255099 | Use of Diketodithiopiperazine Antibiotics for the Preparation of Antiangiogenic Pharmaceutical Compositions - The invention relates to the use of diketodithiopiperazine antibiotics, in particular chaetocin and gliotoxin, for the preparation of pharmaceutical compositions for antitumor therapy. | 10-16-2008 |